Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

Major U.S. equities indexes were lower at midday Tuesday, with Palantir Technologies leading tech stocks lower.

Sarepta Therapeutics' shares plunged nearly 30% on Tuesday as the failure of two of its approved drugs in a key trial and ...

Monday after the biotechnology company disclosed disappointing drug-trial data, which could lengthen the timeline of the ...

Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance. Though the biotech ...

Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...

Sarepta Therapeutics' shares plunged nearly 40% in premarket trading on Tuesday as failure of two of its approved drugs for a ...

Shares plunge 36% after nine-year DMD drug trial misses endpoint. Q3 revenue beats but clinical failure dominates sentiment.

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Sarepta Therapeutics delivered a disastrous third-quarter earnings performance. A long-delayed confirmatory clinical trial of ...

Shares of Sarepta Therapeutics declined after it swung to a third-quarter loss and reported two of its therapies didn't meet statistical significance in a recent trial. The stock slid 36% to $15.67 in ...

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...